Table 1.
Baseline characteristics of MS‐patients and HC
| Healthy controls | MS patients | P | MS patient subgroups (disease course) | ||||
|---|---|---|---|---|---|---|---|
| CIS |
RR MS |
SP MS |
PP MS |
||||
| N (%) | 259 | 259 |
11 (4.2) |
178 (68.7) |
56 (21.6) |
14 (5.4) |
|
| Sex male (%) | 81 (31.3) | 78 (30.1) | 0.849 | 4 (36.4) | 40 (22.5) | 27 (48.2) |
7 (50) |
| Age (mean ± (sd)) | 44.31 (11.26) | 44.42 (11.06) | 0.909 | 36.04 (7.95) | 41.74 (10.32) | 53.77 (8.86) | 47.70 (7.22) |
|
Genetic Poly‐ morphism N (%) |
0.446 | ||||||
|
AA (Met/Met) |
10 (4.8) |
7 (2.7) |
1 (9.1) |
5 (2.8) |
1 (1.8) |
0 (0) |
|
|
AG (Met/Val) |
69 (33.2) |
81 (31.8) |
1 (9.1) | 55 (31.2) | 22 (40.0) | 3 (23.1) | |
| GG (Val/Val) | 129 (62.0) | 167 (65.5) | 9 (81.8) | 116 (65.9) | 32 (58.2) | 10 (76.9) | |
| Disease Duration inyears(mean ± (sd)) | n.a. | 8.58 (7.34) | 1.70 (1.70) | 7.89 (6.48) | 12.64 (8.79) | 5.93 (6.39) | |
| EDSS (mean ± (sd)) | n.a. | 1.41 (0.80) | 2.61 (1.37) | 4.95 (1.35) | 4.64 (1.43) | ||
|
No MS medication N (%) |
n.a. | 97 (37.5) | 8 (72.7) | 56 (31.5) | 19 (33.9) | 14 (100) | |
|
MS medication N (%) |
n.a. | 162 (62.5) | 3 (27.3) | 122 (68.5) | 37 (66.1) | 0 (0.0) | |
| Fumaric acid | 1 (0.4) |
0 (0.0) |
1 (0.5) |
0 (0.0) |
0 (0.0) |
||
| Glatiramer acetate | 33 (12.7) |
0 (0.0) |
29 (16.3) | 4 (7.2) |
0 (0.0) |
||
| Interferon β‐1a i.m. | 25 (9.7) | 3 (27.3) | 21 (11.8) | 1 (1.8) |
0 (0.0) |
||
| Interferon β‐1a s.c. | 40 (15.4) |
0 (0.0) |
35 (19.7) | 5 (8.9) |
0 (0.0) |
||
| Interferon β‐1b s.c. | 56 (21.6) |
0 (0.0) |
34 (19.1) | 22 (39.3) |
0 (0.0) |
||
| Mitoxantrone | 7 (2.7) |
0 (0.0) |
2 (1.1) |
5 (8.9) |
0 (0.0) |
||
CIS, clinically isolated syndrome; RRMS, relapsing remitting MS; SPMS, secondary progressive MS; PPMS, primary progressive MS. P values refer to HC versus all MS patients.